NCT03659201已完成4 期
Randomized Clinical Trial, Placebo Controlled and Active Comparator, to Evaluate Efficacy and Safety of Neosil in Chronic Effluvium
EMS1 个研究点 分布在 1 个国家目标入组 232 人开始时间: 2018年9月3日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 232
- 试验地点
- 1
- 主要终点
- Hair density
研究概览
简要总结
The purpose of this study is to evaluate the efficacy of Neosil in the treatment of chronic effluvium
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Participants who present hair loss for more than 6 months;
- •Do not use other possible cosmetic or dermatological treatments, during the trial;
- •Not change the diet during the trial and not be any restrictive diet during this period.
排除标准
- •Pregnancy or risk of pregnancy and lactating patients;
- •Use of any products to promote hair growth within the 6 months prior to the Baseline Visit;
- •History of hair transplants;
- •Current skin disease;
- •History hypersensitivity to the active ingredients used in the study;
- •Participation in clinical trial in the year prior to this study;
- •Known history of non controled systemic disease (diabetes, hypertension, anemia, iron deficiency, and others);
- •Gastric diseases;
- •History of systemic disease (HIV, non specify autoimmune disease, hepatitis, and others).
研究组 & 干预措施
Neosil complete
Experimental
The patient will take the tablets, as follow:
3 tablets of Neosil, Oral, per day - during the initial 12 weeks; and
2 tablets of Neosil Oral, per day - during the last 12 weeks.
干预措施: Neosil complete (Drug)
Pantogar
Experimental
The patient wil take the tablets, as follow:
3 tablets of Placebo, Oral, per day - during the initial 12 weeks; and
3 tablets of Pantogar, Oral, per day - during the last 12 weeks.
干预措施: Pantogar (Drug)
Neosil
Experimental
The patient will take the tablets, as follow:
2 tablets of Neosil Oral, per day - during the 12 weeks.
干预措施: Neosil (Drug)
结局指标
主要结局
Hair density
时间窗: 24 weeks
次要结局
- Incidence and severity of adverse events recorded during the study(24 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
To Assess the Safety and Efficacy of Ciclesonide, Applied as a Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (BY9010/M1-401)Rhinitis, Allergic, SeasonalHay FeverNCT00659841AstraZeneca302
已完成
3 期
A Study of Ciclesonide Nasal Spray in Patients 18 Years and Older With Seasonal Allergic Rhinitis (BY9010/M1-413)Rhinitis, Allergic, SeasonalHay FeverNCT00384475AstraZeneca500
已完成
3 期
To Assess the Safety and Efficacy of Ciclesonide Applied as a Nasal Spray in the Treatment of Perennial Allergic Rhinitis (BY9010/M1-402)Rhinitis, Allergic, PerennialNCT00659750AstraZeneca418
已完成
3 期
Safety and Effectiveness of Ciclesonide Nasal Spray in Patients With Perennial Allergic Rhinitis During One Year Treatment (BY9010/M1-404)Hay FeverAllergic RhinitisPerennial Allergic RhinitisNCT00163501AstraZeneca600
已完成
3 期
Safety and Effectiveness of Ciclesonide Nasal Spray in Children (6 to 11 Years) With Perennial Allergic Rhinitis (BY9010/M1-403)Hay FeverAllergic RhinitisPerennial Allergic RhinitisNCT00163514AstraZeneca636